Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Dermata Therapeutics, Inc. - Warrant (NQ:DRMAW)

0.0171 -0.0014 (-7.57%)

Streaming Delayed Price Updated: 10:39 AM EDT, Mar 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	8,433
Open	0.0172
Bid (Size)	0.0148 (8,400)
Ask (Size)	0.0184 (12,600)
Prev. Close	0.0185
Today's Range	0.0171 - 0.0172
52wk Range	0.0111 - 0.0440
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

March 10, 2026

Via ACCESS Newswire

Dermata Opens a New Chapter with the Release of Tome Skincare

March 05, 2026

Via ACCESS Newswire

Performance

YTD	-7.6%	-7.6%
1 Month	-11.4%	-11.4%
3 Month	-8.1%	-8.1%
6 Month	-1.2%	-1.2%
1 Year	-11.9%	-11.9%

More News

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

January 20, 2026

Via ACCESS Newswire

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 29, 2025

Via ACCESS Newswire

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 24, 2025

Via ACCESS Newswire

Dermata to Present on BioPub on January 31, 2025

January 29, 2025

Via ACCESS Newswire

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

December 16, 2024

Via ACCESSWIRE

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

December 10, 2024

Via ACCESSWIRE

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

December 04, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 14, 2025

Via ACCESS Newswire

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

October 02, 2025

Via ACCESS Newswire

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

September 17, 2025

Via ACCESS Newswire

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

September 16, 2025

From Virtual Investor Conferences

Via GlobeNewswire

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 03, 2024

Via ACCESSWIRE

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

September 10, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 13, 2025

Via ACCESS Newswire

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

July 08, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025

Via ACCESS Newswire

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

April 15, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 13, 2024

Via ACCESSWIRE

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

March 27, 2025

Via ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

March 17, 2025

Via ACCESS Newswire

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

February 25, 2025

Via ACCESS Newswire

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 22, 2025

Via ACCESS Newswire

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

January 21, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Dermata Therapeutics, Inc. - Warrant publicly traded?

Yes, Dermata Therapeutics, Inc. - Warrant is publicly traded.

What exchange does Dermata Therapeutics, Inc. - Warrant trade on?

Dermata Therapeutics, Inc. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Dermata Therapeutics, Inc. - Warrant?

The ticker symbol for Dermata Therapeutics, Inc. - Warrant is DRMAW on the Nasdaq Stock Market

What is the current price of Dermata Therapeutics, Inc. - Warrant?

The current price of Dermata Therapeutics, Inc. - Warrant is 0.0171

When was Dermata Therapeutics, Inc. - Warrant last traded?

The last trade of Dermata Therapeutics, Inc. - Warrant was at 03/17/26 10:39 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.